BioNTech Results Presentation Deck

SITC 2021 - BNT411 Phase 1/2: Tolerable Safety Profile and Encouraging Pharmacodynamic Signals with Monotherapy at All Doses Small molecule immunomodulator designed to activate both the adaptive and innate immune system through the TLR-7 pathway 30 BNT411 monotherapy: 11 patients Median age 62 years Previously received 2-5 systemic cancer therapies 5 of 8 DLs cleared in Part 1 A ● Solid tumors N-60 Dose escalation ● BNT411 monotherapy Patients with metastatic or unresectable solid tumors (ECOG 0 or 1) that have exhausted available treatment options BNT411 + chemotherapy and checkpoint inhibition Patients with chemotherapy-naïve Tolerable safety profile and no DLTS tested to-date ES-SCLC Only drug-related AEs: Pyrexia (n=2), grades 1 & 3 (non-serious) Anemia (n=2), grades 1 & 2 Expansion cohorts Preliminary biological activity consistent with mechanism of action Plasma cytokine levels were highest. at DL5 (2.4 µg/kg) in 3/4 of patients Interferon-y induced protein (IP10) increased 2.7-9.2-fold Data cutoff:1 July 2021. ECOG, Eastern Cooperative Oncology Group; ES-SCLC, extensive-stage small cell lung cancer; AE, adverse event; DL, dose level; DLT, dose-limiting toxicity BIONTECH

View entire presentation